The associations between arginine-based metabolites and incident type 2 diabetes (T2D) are unknown. We employed a case-cohort design, nested within the PREDIMED trial, to examine vs. Q1 0.52, 95% CI 0.22, 1.25; P trend = 0.04) were associated with a lower risk of T2D. Positive changes of citrulline and ornithine, and negative changes in SDMA and arginine/(ornithine + citrulline) were associated with concurrent 1-year changes in homeostatic model assessment of insulin resistance. Individuals in the low-fat-diet group had a higher risk of T2D for 1-year
Funding information
vs. Q1 0.52, 95% CI 0.22, 1.25; P trend = 0.04) were associated with a lower risk of T2D. Positive changes of citrulline and ornithine, and negative changes in SDMA and arginine/(ornithine + citrulline) were associated with concurrent 1-year changes in homeostatic model assessment of insulin resistance. Individuals in the low-fat-diet group had a higher risk of T2D for 1-year
| INTRODUCTION
Arginine is a key amino acid that is at the nexus of several important pathways hypothesized to be involved in type 2 diabetes (T2D) development. 1 Derivatives of arginine include the urea cycle metabolites, arginine, citrulline, ornithine and methylarginines, including N-monomethyl-l-arginine (NMMA), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Interventions involving these metabolites may potentially delay or prevent T2D onset. ; however, the biological mechanisms by which a Mediterranean diet can reduce T2D risk, and whether a Mediterranean diet may offset an unfavourable metabolite profile, remain unsettled.
The present study was a case-cohort study of participants free of diabetes at baseline, nested within the PREDIMED trial. Our objectives were to address: (1) whether 1-year changes in arginine-based metabolites were associated with T2D; (2) whether 1-year changes in these metabolites were associated with concurrent changes in insulin resistance; and (3) whether a Mediterranean diet intervention could counteract the harmful consequences of an unfavourable metabolite profile.
| METHODS

| Study design and population
We used a case-cohort design, nested within the PREDIMED study The study population comprised a random subcohort from the PREDIMED trial who were free of diabetes at baseline and had available plasma samples, and all incident cases of T2D that occurred in the full trial. The institutional review board of each of the recruitment centres approved the study protocol, and participants provided written informed consent.
| Covariate assessment
At baseline and at yearly follow-up visits, a questionnaire about lifestyle variables (diet, physical activity, smoking), history of illnesses, medication use and family history of disease was administered.
Trained personnel ascertained anthropometric and blood pressure measurements. Hypercholesterolaemia and hypertension were based on physician diagnosis or medication use. The Mediterranean diet score was based on a validated 14-item screener (0, no adherence; 14, maximum adherence). 3 
| Blood specimens and metabolite profiling
Fasting blood samples were collected at baseline and at yearly intervals thereafter throughout follow-up. Urea cycle metabolites (arginine, citrulline, ornithine), and methylarginines (ADMA, SDMA, NMMA)
were analysed using a targeted approach (Broad Institute). Raw data were obtained and processed using liquid chromatography tandem mass spectrometry, as previously described. 5 The coefficient of variation for each metabolite was: arginine, 2.5%; ornithine, 2.4%; citrulline, 2.1%; ADMA, 7.2%; SDMA, 4.5%; NMMA, 5.5%.
Fasting glucose and insulin were also determined from these plasma samples. Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated (HOMA-IR = fasting insulin * fasting glucose/22.5, where insulin is in μU/mL and glucose is in mmol/L) at baseline and 1 year.
| Assessment of T2D
The adjudication of new-onset cases of T2D during follow-up was performed in a blinded fashion by the Clinical Endpoint Committee of the PREDIMED, an ad hoc panel of physicians. 3 A patient was considered to have diabetes if they had two confirmations of fasting plasma glucose ≥7.0 mmol/L or 2-hour plasma glucose ≥11.1 mmol/L, after a 75-g oral glucose load.
| Statistical analysis
Metabolite values were first normalized using an inverse normal transformation. Our estimates therefore have the interpretation of the HR of T2D per 1-SD increase in the exposure. For example, a 2.00 HR per 1-SD increase would mean that an individual with a plasma concentration of a given metabolite that is 1 SD above that of another individual would have twice the relative rate of T2D incidence of that individual.
We also considered a pre-hypothesized arginine/ADMA ratio, 6 as well as the global arginine bioavailability ratio (GABR) defined as arginine/ (citrulline + ornithine) in our primary analysis. 7 We fitted Cox regression models, stratified by recruitment centre, using inverse probability weights and employing a sandwich variance estimator. 8 We also tested potential effect modification by intervention group on the relationship between 1-year changes in metabolites and T2D using likelihood ratio tests. Finally, we examined the association between 1-year changes in plasma metabolites with concurrent 1-year changes of continuous HOMA-IR among patients with valid insulin and glucose measurements at baseline and 1 year by using generalized estimating equations. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
| RESULTS
Our study population comprised 892 participants (641 non-cases, 251 cases; median follow-up time 3.8 years) at baseline and 655 participants (497 non-cases, 158 cases) with available samples after 1 year. Figure S1 shows the study population flow chart. Table S1 provides the descriptive characteristics of the 694 individuals in the subcohort according to baseline arginine levels.
3.1 | One-year changes in metabolites and risk of T2D Table 1 shows the results of the 1-year change analysis of metabolites and ratios with T2D. The 1-year changes in arginine were inversely associated with T2D risk (HR per SD 0.68, 95% CI 0.49, 0.95). The arginine/ADMA ratio showed a trend towards statistical significance, with individuals in higher quartiles of change in this ratio demonstrating a lower risk of T2D (P trend = 0.04).
We also tested potential effect modification by intervention group on the association between 1-year changes in metabolites and T2D risk. 
| DISCUSSION
In the present prospective case-cohort study of 892 participants nested in the PREDIMED trial, we found a negative association for 1-year changes in arginine and arginine/ADMA ratio with the risk of T2D in individuals at high cardiovascular risk. Furthermore, positive changes in ornithine and citrulline, and negative changes in SDMA and GABR were associated with concurrent changes in HOMA-IR.
We found significant effect modification by intervention on the association between 1-year changes in NMMA and T2D risk.
Our results for incident T2D and HOMA-IR are largely consistent with previous reports, although none of them had assessed an intervention or used repeated measurements. A large body of literature supports an inverse association of arginine with cardiometabolic disease, 9 although the underlying mechanisms are not fully elucidated.
One putative mechanism is the formation of nitric oxide (NO) from l-arginine by NO synthase in pancreatic β cells. 10 Arginine is required for the production of NO via catalysis to citrulline by NO synthase (NOS), 11 and the prevailing hypothesis is that greater arginine bioavailability may stimulate NO production and insulin sensitivity 12, 13 ; thus, disturbances in the arginine-NO pathway may underlie both CVD and T2D pathogenesis through similar mechanisms, such as chronic inflammation, mitochondrial dysfunction and oxidative stress. [14] [15] [16] Nevertheless, a potential role for arginine in the primary prevention of diabetes is still debated.
In the present analysis of HOMA-IR, we found two metabolites associated with positive changes in HOMA-IR, ornithine and citrulline, and two metabolites associated with negative changes in HOMA-IR, SDMA and GABR. Ornithine may be considered a marker of low arginine bioavailability as a substrate of NOS. 17 However, our finding that SDMA was inversely associated with HOMA-IR is surprising given the established role of SDMA in inhibiting NOS and its positive association with CVD. 18 Since low SDMA concentration is a validated marker of high glomerular filtration rate, 19 significant inverse associations of SDMA with T2D may be a marker for hyperfiltration characteristic of prediabetes. 20 Lastly, we found a significant modification effect by the Mediterranean diet intervention on the relationship between 1-year changes in NMMA and T2D, suggesting that harmful changes in plasma NMMA may be offset by consuming a Mediterranean diet. Taking into consideration results of numerous primary studies, we continue to recommend a Mediterranean diet, supplemented with either EVOO or nuts, rather than a low-fat control diet for the prevention of cardiometabolic disease. 3   TABLE 1 Hazard ratios (95% CI The present study has several strengths. We used an efficient case-cohort design to evaluate associations of metabolites with incident T2D. We were able to adjust for multiple confounders, as well as test for several potential effect modifiers with sufficient power. Limitations include the fact that T2D was initially specified as a secondary outcome. In addition, we cannot exclude the possibility of residual and unmeasured confounding, and there could also have been selection bias if the distribution of metabolites was unequal among missing and non-missing blood specimens. Finally, our analysis among predominately white individuals at high risk of CVD may not be generalizable to other populations.
We conclude that arginine bioavailability is important in T2D pathophysiology. Specifically, we report inverse associations of 1-year changes in arginine and arginine/ADMA ratio with the risk of incident T2D. Baseline ornithine was also predictive of higher T2D risk. Positive changes in ornithine and citrulline, and negative changes in SDMA and GABR, were inversely associated with concurrent changes in HOMA-IR. Lastly, a Mediterranean diet may counteract harmful changes in plasma NMMA with respect to T2D.
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